Notice of Intent to Publish a Funding Opportunity Announcement for Generate A Precision Medicine Intergenerational Resource for the Study of Factor VIII Immunogenicity in Severe Hemophilia A:Clinical Coordinating Center
ID: 322896Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/322896
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the establishment of a Clinical Coordinating Center aimed at generating a Precision Medicine Intergenerational Resource for the study of Factor VIII immunogenicity in severe Hemophilia A. This initiative will utilize a UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement, allowing for a total of up to seven years of support, contingent upon the successful completion of core milestones over the initial three-year phase and subsequent four-year phase. The funding opportunity, which has an estimated total program funding of $2,060,000 and an award ceiling of $1,338,000, is designed to facilitate the development of a comprehensive resource that will enhance understanding and treatment of severe Hemophilia A. Interested applicants can reach out to Dr. Iman K. Martin at iman.martin@nih.gov or by phone at 301-435-0065 for further information, with the anticipated award date set for January 5, 2021.

    Point(s) of Contact
    Iman K. Martin, PhD, MPH, MS
    (301) 435-0065
    iman.martin@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the continuation of the NIDDK Hematology Central Coordinating Center (HCC) under a cooperative agreement. The HCC will collaborate with up to five Cooperative Centers of Excellence in Hematology (CCEH) to provide administrative support, develop communication strategies, and implement educational programs aimed at enhancing research in nonmalignant hematology. This initiative is crucial for fostering a national multidisciplinary research effort to study hematopoiesis and address nonmalignant hematologic diseases. The estimated total program funding is $1 million, with a single award anticipated, and the NOFO is expected to be published in December 2024, with applications due by March 2025. For further details, potential applicants should prepare to submit their proposals in alignment with the requirements outlined in the forthcoming NOFO.
    Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the continuation of the NIDDK Hematology Central Coordinating Center (HCCC) through a cooperative agreement, aimed at enhancing collaboration among up to five Cooperative Centers of Excellence in Hematology. The HCCC will provide essential administrative and communication support, manage a Pilot and Feasibility Program, and promote research addressing nonmalignant hematologic diseases and normal hematopoiesis. This initiative is crucial for invigorating the field of hematology, fostering partnerships, and ensuring diverse perspectives in research teams. Interested applicants can find more information and apply by March 18, 2025, with an estimated funding amount of up to $1,000,000. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-023.html.
    Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the establishment of a Clinical Coordinating Center (CCC) to support multi-site investigator-initiated clinical trials under the UG3/UH3 cooperative agreement mechanism. This initiative aims to facilitate trials focused on efficacy, comparative effectiveness, and implementation research, particularly those that address health disparities and promote community engagement. Eligible applicants include a diverse range of organizations, such as academic institutions, nonprofit entities, and tribal governments, with applications required to detail project management, participant recruitment strategies, and a Plan for Enhancing Diverse Perspectives (PEDP). The application period opens on January 11, 2025, with a submission deadline of September 11, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the development of a Clinical Coordinating Center (CCC) to support multi-site investigator-initiated clinical trials under the UG3/UH3 activity codes. This initiative aims to foster innovative trial designs relevant to the National Heart, Lung, and Blood Institute's (NHLBI) research mission, requiring comprehensive project plans that address participant recruitment, milestone achievements, and strategies for enhancing community engagement and diversity. The funding mechanism is bi-phasic and necessitates simultaneous applications for both a CCC and a collaborating Data Coordinating Center (DCC), emphasizing strong project management and a commitment to minimizing health disparities. Interested applicants must submit their proposals by September 11, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found in the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-192.html.
    Enhancing Public Health Surveillance of Bleeding Disorders
    Active
    Centers for Disease Control - NCBDDD
    The Centers for Disease Control and Prevention (CDC) is forecasting a cooperative agreement opportunity titled "Enhancing Public Health Surveillance of Bleeding Disorders." This initiative aims to collect and utilize surveillance data from federally supported hemophilia treatment centers to inform policies and clinical practices related to hemophilia, von Willebrand disease, and other inherited bleeding disorders, ultimately seeking to reduce health complications and improve the quality of life for affected individuals. The program is critical for understanding treatment practices, monitoring health complications, and identifying causes of death among those with bleeding disorders. The estimated total program funding is $21.5 million, with individual awards ranging from $100,000 to $4.3 million. Interested applicants can reach out to Brandi Dupervil at (404) 498-6879 or via email at inm4@cdc.gov, with applications due by May 15, 2025, and an anticipated award date of August 31, 2025.
    Notice of Intent to Publish a Notice of Funding Opportunity for Coordination Center for the Alzheimer�s Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Coordination Center for the Alzheimer’s Disease Sequencing Project Consortium, aimed at advancing research in Alzheimer's disease genetics. This initiative, which follows the approval of the concept by the National Advisory Council on Aging, will invite applications under an open competition framework, expanding eligibility for potential applicants. The funding opportunity is critical for fostering collaborations and innovative projects in the field of health, with an estimated total program funding of $1.6 million and a maximum award ceiling of $1 million for the selected applicant. The NOFO is expected to be published in November 2024, with applications due by February 14, 2025, and awards anticipated to be made by September 1, 2025.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Somatic Cell Genome Editing Translational Coordination and Dissemination Center (U24, Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the establishment of a Somatic Cell Genome Editing Translational Coordination and Dissemination Center (TCDC) as part of its Somatic Cell Genome Editing (SCGE) program. The objective of this initiative is to accelerate the development of genome editing therapeutic agents by facilitating Investigational New Drug (IND) application enabling studies, establishing regulatory approval pathways, and disseminating successful strategies for initiating first-in-human clinical trials. This funding opportunity is crucial for advancing innovative therapeutic approaches in health, with an estimated total program funding of $2 million and the expectation of one award. Interested applicants can reach out to Dr. Marrah Lachowicz-Scroggins at SCGEprogram@od.nih.gov or by phone at 301-827-8229 for further details, with the anticipated application due dates in Summer 2022 and an estimated award date of April 1, 2023.
    Notice of Intent to Publish a Funding Opportunity Announcement for Data Management and Coordinating Center (DMCC) for Rare Diseases Clinical Research Network (RDCRN) (U2C Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the establishment of a Data Management and Coordinating Center (DMCC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases by facilitating collaborative, multi-site, patient-centric research through the RDCRN and supporting the activities of the Rare Diseases Clinical Research Consortia (RDCRC). The estimated total program funding for this grant is $1,000,000, with the FOA expected to be published in 2024 and awards anticipated in 2025. Interested applicants can reach out to Dr. Tiina K. Urv at urvtiin@mail.nih.gov or by phone at 301-827-2746 for further information.